MX340626B - Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos. - Google Patents

Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos.

Info

Publication number
MX340626B
MX340626B MX2012013470A MX2012013470A MX340626B MX 340626 B MX340626 B MX 340626B MX 2012013470 A MX2012013470 A MX 2012013470A MX 2012013470 A MX2012013470 A MX 2012013470A MX 340626 B MX340626 B MX 340626B
Authority
MX
Mexico
Prior art keywords
levoisovalerylspiramycin
iii
preparations
preparation methods
injection
Prior art date
Application number
MX2012013470A
Other languages
English (en)
Other versions
MX2012013470A (es
Inventor
Jiang Yang
Hao Yuyou
Original Assignee
Shenyang Tonglian Group Co Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Tonglian Group Co Ltd * filed Critical Shenyang Tonglian Group Co Ltd *
Publication of MX2012013470A publication Critical patent/MX2012013470A/es
Publication of MX340626B publication Critical patent/MX340626B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen la levoisovalerilespiramicina I,II o III, preparaciones, métodos de preparación y sus usos. Las preparaciones comprenden levoisovalerilespiramicina I, II,o III y vehiculo fasrmaceuticamente aceptable y/o adyuvante, en donde la pureza de levoisovalerilesparamicina I, II, III está por encima de 90% en peso. La de levoisovalerilesparamicina I, II o III tiene una buena actividad antibacteriana, y las preparaciones incluyen soluciones para inyección. Polvo para inyección o polvo liofilizado para inyección.
MX2012013470A 2010-05-25 2011-05-25 Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos. MX340626B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201010182109 2010-05-25
CN201010182111 2010-05-25
CN201010182108 2010-05-25
PCT/CN2011/074644 WO2011147313A1 (zh) 2010-05-25 2011-05-25 左旋异戊酰螺旋霉素i、ii或iii，及其制剂、制备方法及应用

Publications (2)

Publication Number Publication Date
MX2012013470A MX2012013470A (es) 2013-03-18
MX340626B true MX340626B (es) 2016-07-18

Family

ID=45003321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013470A MX340626B (es) 2010-05-25 2011-05-25 Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos.

Country Status (15)

Country Link
US (1) US8778896B2 (es)
EP (3) EP2578595B1 (es)
JP (1) JP5945868B2 (es)
KR (2) KR101706518B1 (es)
BR (1) BR112012029913B1 (es)
CA (3) CA2915222C (es)
DK (3) DK2578595T3 (es)
ES (3) ES2754614T3 (es)
MX (1) MX340626B (es)
MY (1) MY164231A (es)
PL (3) PL3210990T3 (es)
PT (1) PT3210990T (es)
RU (3) RU2593498C2 (es)
WO (1) WO2011147313A1 (es)
ZA (3) ZA201209738B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633737T3 (es) * 2010-05-25 2017-09-25 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Levocarrimicina, composiciones farmacéuticas, procedimientos de preparación y utilizaciones de la misma
CN105497053B (zh) * 2015-12-31 2018-02-13 沈阳福洋医药科技有限公司 可利霉素在抗结核分枝杆菌感染中的应用
RU2766176C2 (ru) * 2017-07-04 2022-02-08 Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата
WO2019141256A1 (zh) 2018-01-19 2019-07-25 沈阳福洋医药科技有限公司 可利霉素或其活性成分的用途
CA3088818A1 (en) * 2018-01-19 2019-07-25 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Mtor inhibitor, pharmaceutical composition and use thereof
CN110384710B (zh) * 2018-04-17 2023-01-10 沈阳福洋医药科技有限公司 一种用于预防和/或治疗疼痛的药物、组合产品及其应用
AU2019254974A1 (en) * 2018-04-17 2020-11-26 Shanghai Tonglian Pharmaceutical Co., Ltd. Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof
JP2022540291A (ja) * 2019-05-16 2022-09-15 沈陽福洋医薬科技有限公司 線維化を予防、緩和及び／又は治療するための薬物、組成製品及びその応用
CN112239483B (zh) * 2019-07-18 2023-10-27 沈阳福洋医药科技有限公司 一种化合物及药物组合物
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5334788A (en) * 1976-09-11 1978-03-31 Sanraku Inc Antibiotics spiramycin derivatives
CN1058295C (zh) 1997-06-03 2000-11-08 中国医学科学院医药生物技术研究所 一种利用基因工程技术制造生技霉素的方法
CN1169947C (zh) * 2002-11-19 2004-10-06 中国医学科学院医药生物技术研究所 必特螺旋霉素的基因工程菌株螺旋霉素链霉菌wsj-195
CN1237976C (zh) * 2003-12-23 2006-01-25 沈阳同联集团有限公司 必特螺旋霉素及其在抗感染性疾病中的应用
JP2008509899A (ja) * 2004-08-12 2008-04-03 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 胃腸管の炎症性疾患治療用の細胞特異的コンジュゲートの使用
CN101054553A (zh) * 2007-04-09 2007-10-17 中国医学科学院医药生物技术研究所 异戊酰螺旋霉素i基因工程菌株的构建
CN101649325B (zh) * 2009-07-03 2011-09-07 中国医学科学院医药生物技术研究所 一种提高基因工程异戊酰螺旋霉素主组分含量的基因串连技术
CN101785779B (zh) 2010-03-09 2014-03-05 沈阳同联集团有限公司 异戊酰螺旋霉素ii的分离制备
CN101773510B (zh) * 2010-03-09 2013-06-05 沈阳同联集团有限公司 异戊酰螺旋霉素iii的分离制备
CN101785778A (zh) 2010-03-09 2010-07-28 沈阳同联集团有限公司 异戊酰螺旋霉素i的分离制备及其应用
ES2633737T3 (es) * 2010-05-25 2017-09-25 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Levocarrimicina, composiciones farmacéuticas, procedimientos de preparación y utilizaciones de la misma

Also Published As

Publication number Publication date
RU2593498C2 (ru) 2016-08-10
RU2647237C1 (ru) 2018-03-14
PL2578595T3 (pl) 2017-10-31
DK3210990T3 (da) 2020-03-23
CA2800021A1 (en) 2011-12-01
CA2800021C (en) 2016-03-22
RU2647236C1 (ru) 2018-03-14
MX2012013470A (es) 2013-03-18
ZA201209738B (en) 2015-04-29
CA2915236A1 (en) 2011-12-01
DK3210991T3 (da) 2019-11-11
JP2013528166A (ja) 2013-07-08
KR101706518B1 (ko) 2017-02-14
DK2578595T3 (en) 2017-07-10
US20130065848A1 (en) 2013-03-14
ES2633723T3 (es) 2017-09-25
ZA201406382B (en) 2015-12-23
US8778896B2 (en) 2014-07-15
CA2915236C (en) 2019-03-12
BR112012029913A2 (pt) 2017-11-28
BR112012029913A8 (pt) 2018-01-09
KR20160017124A (ko) 2016-02-15
BR112012029913B1 (pt) 2021-02-02
JP5945868B2 (ja) 2016-07-13
EP2578595A4 (en) 2013-11-06
EP3210991A1 (en) 2017-08-30
ZA201406381B (en) 2016-08-31
CA2915222A1 (en) 2011-12-01
EP2578595B1 (en) 2017-04-19
PL3210990T3 (pl) 2020-10-05
CA2915222C (en) 2019-03-12
EP3210990B1 (en) 2020-01-01
EP2578595A1 (en) 2013-04-10
PL3210991T3 (pl) 2020-03-31
WO2011147313A1 (zh) 2011-12-01
EP3210990A1 (en) 2017-08-30
ES2754614T3 (es) 2020-04-20
KR20130041829A (ko) 2013-04-25
PT3210990T (pt) 2020-04-01
RU2012156420A (ru) 2014-06-27
ES2781425T3 (es) 2020-09-02
MY164231A (en) 2017-11-30
EP3210991B1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
MX340626B (es) Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos.
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
NZ622566A (en) Chromobacterium bioactive compositions and metabolites
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2010004576A (es) Derivados de pirimidina novedosos.
MX348823B (es) Formulaciones estables de linaclotida.
NZ602328A (en) Novel compounds and compositions for targeting cancer stem cells
MX349132B (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
TW200942524A (en) Novel aminomethyl benzene derivatives
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
TN2015000090A1 (en) Daptomycin formulations and uses thereof
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
UA111599C2 (uk) Композиція каспофунгіну
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
PH12014502465A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
MX2012007590A (es) Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral.
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
MX2011010359A (es) Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
WO2014062838A3 (en) Pkm2 modulators and methods for their use
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX344189B (es) Formulaciones de mazindol.

Legal Events

Date Code Title Description
FG Grant or registration